+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Urokinase and urokinase receptor overexpression in breast carcinoma as compared to benign lesions



Urokinase and urokinase receptor overexpression in breast carcinoma as compared to benign lesions



Proceedings of the American Association for Cancer Research Annual Meeting 34: 64




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034144104

Download citation: RISBibTeXText


Related references

Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: An immunohistochemical comparison of normal, benign, and malignant breast tissues. Cancer 77(6): 1079-1088, 1996

Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions. Blood Coagulation & Fibrinolysis 15(5): 383-391, 2004

Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Research 53(13): 3198-3206, 1993

Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry. Histochemistry & Cell Biology 110(1): 27-32, 1998

Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor. Journal of Biological Chemistry 269(41): 25668-25676, 1994

Overexpression of plasminogen activator inhibitor type 1 in breast carcinoma cells upregulates urokinase receptor. Proceedings of the American Association for Cancer Research Annual Meeting 38: 412, 1997

Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic a2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor. The Journal of Biological Chemistry 269: 668-76, 1994

The decrease in cell migration of a derived ovarian carcinoma cell line with defective urokinase production and normal urokinase receptor expression is not corrected by addition of urokinase A possible explanation. Fibrinolysis 8(Suppl. 1): 59, 1994

Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells. International Journal of Cancer 98(5): 656-664, 2002

Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Research 59(20): 5307-5314, 1999

Comparative distribution of urokinase receptor and urokinase in human breast cancer. Proceedings of the American Association for Cancer Research Annual Meeting 35: 74, 1994

Fibrinolytic effects of pro-urokinase combined with low-dose urokinase compared to high-dose urokinase in patients with acute myocardial infarction. Thrombosis Research 67(2): 191-200, 1992